 |
NHMRC Clinical Trials Centre |
 |
 |
 |
 |
 |
 |
 |
 |
||
| Trials | |
| Cancer trials | |
| Cardiovascular trials | |
| Other trials | |
| ASPIRE | |
| BOOST II | |
| INIS | |
| Trial support | |
| Trials registry | |
Trials > Trial acronyms
CTC trials: names and abbreviations
| ABC: | Phase II trial of gemcitabine in fixed dose rate infusion compared with cisplatin in patients with biliary tract carcinoma |
| Accelerated BEP: | Accelerated bleomycin, etoposide, cisplatin, pegfilgastrim as first-line chemotherapy for advanced germ-cell tumours |
| AG 9401: | Early versus delayed chemotherapy for asymptomatic metastatic colorectal cancer |
| AG 9601: | A phase II feasibility study of preoperative and postoperative chemotherapy using epirubicin, cisplatin and protracted venous infusion fluorouracil (ECF) in patients with advanced but operable gastric cancer |
| AG 9801: | Phase II study of irinotecan, leucovorin and fluorouracil in advanced gastric cancer |
| ANZ 0001: | A phase III trial of oral chemotherapy with capecitabine versus standard chemotherapy with CMF for advanced breast cancer |
| ANZGOG 0201: | Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer |
| ANZGOG 0401: | Phase II study to evaluate maintaining haemoglobin levels above 120 g/L vs over 100 g/L (HOSTT) |
| ASPIRE: | Aspirin to prevent recurrent venous thromboembolism |
| ATLAS: | Adjuvant tamoxifen: longer against shorter |
| ATTAX: | Phase II study evaluating a weekly schedule of docetaxel with cisplatin and 5-fluorouracil or capecitabine |
| ATTAX2: | Phase II study of cetuximab plus docetaxel in docetaxel-refractory patients with EGFR-positive cancer |
| BIG02: | Exemestane versus tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years (IBCSG 16) |
| BIG2-98: | Docetaxel sequentially or in combination with doxorubicin, followed by CMF (cyclophosphamide methotrexate and 5-fluorouracil), compared with doxorubicin alone or in combination with cyclophosphamide, followed by CMF, in the adjuvant treatment of node-positive breast cancer patients (IBCSG 20) |
| BOOST II | Benefits of oxygen saturation targeting, trial II |
| C-06: | Oral uracil/ftorfur (UFT) plus leucovorin (LV) compared with 5-fluorouracil (5-FU) plus LV in the treatment of patients with stages II and III carcinoma of the colon |
| C-07: | 5-fluorouracil (5-FU) plus leucovorin1 (LV) and oxaliplatin compared with 5-FU plus LV for the treatment of patients with stages II and III carcinoma of the colon |
| Calypso: | Caelyx in platinum-sensitive ovarian cancer patients |
| CD 117: | Phase III randomized, intergroup, international trial assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the KIT receptor tyrosine kinase |
| Chemo & cognition: | Cognitive function and treatment for testicular cancer |
| CO-17: | Phase III randomised study of cetuximab (Erbutix, C225) and best supportive care versus best supportive care in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma |
| Da Vinci: | Phase III trial of irinotecan versus irinotecan + De Gramont schedule 5-fluorouracil and folinic acid in patients with previously treated metastatic colorectal cancer |
| E1292: | Perioperative 5-fluorouracil after resection for patients with colon cancer. |
| E6290: | Adjuvant chemoradiation after resection for gastric
adenocarcinoma. AGITG contributed six patients to the recruitment
target of 550. |
| ECOG 2288: | A prospectively randomised trial of low-dose leucovorin + 5-fluorouracil, high-dose leucovorin + 5-fluorouracil, levamisole + 5-fluorouracil, or low-dose leucovorin + 5-fluorouracil + levamisole following curative resection in selected patients with Dukes' B or C colon cancer. |
| EORTC 40983: | Preoperative and postoperative chemotherapy with oxaliplatin 5FU/LV versus surgery alone in resectable liver metastases of colorectal origin |
| EORTC 55041: | Phase III study of erlotinib versus observation (Tarceva) |
| EORTC 62005:: | P hase III study of two different doses of imatinib mesylate in patients with CD117-expressing metastatic or unresectable gastrointestinal stromal tumor |
| ESPAC-3 | Phase III adjuvant trial in pancreatic cancer comparing: 5-fluorouracil + D-L folinic acid with gemcitabine or no adjuvant treatment |
| FIELD: | Fenofibrate intervention and event lowering in diabetes |
| Gofurtgo: | Phase II study of fixed dose rate gemcitabine-oxaliplatin with 5-fluorouracil and radiotherapy to treat localised pancreatic cancer |
| GOG 0201: | Phase II trial of weekly docetaxel (Taxotere) for patients with relapsed ovarian cancer who have previously received paclitaxel |
| GOG 182: | A phase III randomised trial of paclitaxel and carboplatin versus triplet or sequential doublet combinations in patients with epithelial ovarian or primary peritoneal carcinoma |
| GOG 191: | Phase III trial to evaluate the efficacy of maintaining haemoglobin levels about 120 g/L with erythropoietin, compared with above 100 g/L without erythropoietin, in anaemic patients receiving concurrent radiation and cisplatin for cervical cancer |
| HABITS: | Hormonal replacement therapy (HRT) after breast cancer-is it safe? Randomised trial of HRT after previous radical breast cancer treatment (IBCSG 17) |
| HOSTT: | Phase II study to evaluate maintaining haemoglobin levels above 120 g/L vs over 100 g/L (ANZGOG 0401) |
| IBCSG 15: | High-dose epirubicin and cyclophosphamide supported
by peripheral blood progenitor cells versus standard chemotherapy
(4 cycles AC and 3 cycles CMF) as adjuvant therapy for high-risk,
operable, stage II or III breast cancer in premenopausal and young
postmenopausal patients IBCSG 16: Exemestane versus tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years (BIG 02) |
| IBCSG 20: | Docetaxel sequentially or in combination with doxorubicin, followed by CMF (cyclophosphamide methotrexate and 5-fluorouracil), compared with doxorubicin alone or in combination with cyclophosphamide, followed by CMF, in the adjuvant treatment of node-positive breast cancer patients (BIG 2-98) |
| IBIS: | International breast intervention study |
| ICBSG 17: | Hormonal replacement therapy (HRT) after breast cancer-is it safe? Randomised trial of HRT after previous radical breast cancer treatment (HABITS) |
| ICON 7: | Randomised, two-arm, multicentre GCIG trial of adding bevacizumab to standard chemotherapy in patients with epithelial ovarian cancer |
| IG 9401: | Randomised trial comparing surgery alone with concurrent preoperative chemotherapy and radiation followed by surgery for localised resectable carcinoma of the oesophagus |
| INIS: | International neonatal immunotherapy study |
| IPOPCIS: | Randomised crossover trial comparing the administration of high-dose chemotherapy as an outpatient regimen or as an inpatient regimen: patient preferences, costs and quality of life |
| LIPID: | Long-term intervention with pravastatin in ischaemic disease |
| MAGIC: | A randomised, controlled trial of pre- and postoperative
chemotherapy in patients with operable gastric and lower oesophageal
cancer Phase III randomised study of cetuximab (Erbutix, C225) and best supportive care versus best supportive care in patients with pretreated metastatic epidermal growth factor |
| MATES: | Maintenance thalidomide in mesothelioma quality of life and prognostic marker study |
| MAX: | Phase II-III study to evaluate the role of Mitomycin C [mitomycin], Avastin [bevacizumab] and Xeloda [capecitabine] in patients with untreated metastatic colorectal cancer |
| Nitro: | Nitroglycerin patches for non-small-cell lung cancer |
| Quasar 2: | Phase III study of capecitabine and bevacizumab as adjuvant treatment of colorectal cancer |
| QUART: | Patient preferences, quality of life and adjuvant radiation therapy for women with early breast cancer |
| SCOTROC 4: | Multicentre randomised trial of carboplatin flat dosing vs intrapatient dose escalation in first-line chemotherapy |
| SNAC: | Sentinel node biopsy versus axillary clearance |
| Tarceva: | Phase III study of erlotinib versus observation (EORTC 55041) |
| TRIPOD: | Phase II trial of intraperitoneal chemotherapy |
| VICTOR: | Phase III randomised, double-blind, placebo-controlled study of rofecoxib (Vioxx) in colorectal cancer patients following potentially curative therapy |
| VIGOUR: | Virtual Coordinating Center for Global Collaborative Cardiovascular Research |
| ZEST: | Zoloft's effects on symptoms and survival time in advanced cancer |